- In older patients with acute myeloid leukemia (AML) admitted to an intensive care unit (ICU), performance status before ICU admission and need for life-sustaining therapies are important prognostic factors that may assist clinicians in making optimal use of resources.
Why this matters
- ICU-related treatment decisions may be better implemented with estimations of patients most likely to benefit.
- Study to investigate outcomes in older adults with AML after first admission to ICU.
- 330 patients were included in the study.
- Median patient age, 69 (range, 60-90) years.
- All patients were newly diagnosed with AML at a single institution in the United States between 2005 and 2013.
- Funding: National Cancer Institute's Federal Share Program.
- 29.1% of patients (96/330) were admitted to the ICU.
- Primary indications for ICU admission: respiratory failure (39%), septic shock (28%), neurological compromise (9%).
- 64% of those alive at discharge remained alive at 1 year.
- Factors significantly associated with increased odds of in-hospital mortality in multivariate analysis:
- Poorer Eastern Cooperative Oncology Group status before ICU: OR, 2.76; 95% CI, 1.24-6.12; P=.013.
- Need for ≥2 life-sustaining therapies: OR, 12.39; 95% CI, 3.10-49.48; P<.001.>
- Retrospective data.